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Abstract: The association of diabetes with inflammatory bowel disease (IBD) remains unclear. The 
risk of diabetes in patients with IBD compared with non-IBD controls was investigated. Using the 
National Health Insurance database of South Korea, 8070 patients with IBD based on the 
International Classification of Disease 10th revision (ICD-10) codes and rare intractable disease 
codes for Crohn’s disease (CD) and ulcerative colitis (UC) were compared with 40,350 non-IBD 
individuals (2010–2014). Newly diagnosed diabetes identified using ICD-10 codes and the 
prescription of anti-diabetic medication by the end of the follow-up period (2016) was investigated. 
During a mean follow-up of 5.1 years, the incidence of diabetes in patients with IBD was 
significantly higher compared with controls after adjusting for serum glucose levels and steroid use 
(23.19 vs. 22.02 per 1000 person-years; hazard ratio (HR), 1.135; 95% confidence interval (CI), 1.048–
1.228). The risk of diabetes was significantly higher in patients with CD (HR, 1.677; 95% CI, 1.408–
1.997), but not in UC (HR, 1.061; 95% CI, 0.973–1.156). The effect of IBD on the development of 
diabetes was significantly more prominent in younger patients (p < 0.001). Patients with CD are at a 
higher risk of diabetes. Regular monitoring for diabetes is recommended, even in younger CD 
patients who do not use steroid medication.  
Keywords: diabetes; epidemiology; inflammatory bowel disease  
 
1. Introduction 
Diabetes is a metabolic disorder characterized by hyperglycemia due to insulin deficiency or 
resistance, which results in impaired glucose utilization and eventual multi-organ damage, affecting 
the eyes, peripheral nerves, cardiovascular and neurovascular structures, and kidneys. 
Approximately 451 million people worldwide are affected by diabetes and the prevalence is expected 
to reach 693 million by 2045 [1]. The global increase in diabetes prevalence has been a major threat to 
healthcare expenditure and public health. In 2017, the global healthcare costs for patients with 
diabetes were estimated at 850 billion USD, and an estimated 5 million deaths were attributed to 
diabetes globally [1].  
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Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), 
is characterized by chronic relapsing inflammation in the gastrointestinal tract related to complex 
interactions among genetic, environmental, gut microbiome, and immunologic factors [2]. 
Extraintestinal manifestations from nearly every organ system are developed in 25–40% of patients 
with IBD [3]. Endocrine and metabolic manifestations in IBD include metabolic bone disease, growth 
retardation, hypogonadism, pubertal delay, lipid abnormalities, and insulin resistance [4]. However, 
insulin resistance and hyperglycemia may be a consequence of steroid use in patients with IBD 
because the steroid induces elevated serum glucose levels via upregulation of hepatic 
gluconeogenesis, inhibition of glucose uptake in adipose tissue, and impairment of insulin action [5]. 
Moreover, there is no epidemiological evidence to support that IBD is a definite risk factor for 
diabetes. In the present study, the incidence and risk factors for diabetes in patients with IBD were 
determined using a nationwide population-based study and compared with subjects in the general 
population.  
2. Materials and Methods 
2.1. Data Sources 
The National Health Insurance (NHI) service is a mandatory, single public health insurance 
system that covers most of the Korean population except for 3% of the population covered by Medical 
Aid due to low income. The NHI database includes demographic information, disease diagnosis, 
medical procedures, treatments, basic laboratory results, and lifestyle [6]. To reduce the burden of 
medical costs, the rare and intractable disease (RID) registration system has been established in South 
Korea for patients with a disease, such as CD, defined as less than 20000 cases. As the number of UC 
patients is currently increasing to more than 20000, UC is considered an intractable disease. Special 
diagnostic codes beginning with the letter V were used to identify RIDs. The RID code is reliable and 
meets the diagnostic criteria set by the NHI, and can only be registered by a physician in South Korea 
[7].  
2.2. Study Population 
A retrospective nationwide cohort study was performed using the NHI database. The National 
Health Screening Cohort based on NHI data from January 2010 to December 2014 was created, and 
patients over 20 years of age with IBD were included. Among them, patients with a history of diabetes 
from 2002 to the time of diagnosis of IBD (index date) were excluded. Patients with IBD were 
identified using International Classification of Disease 10th revision (ICD-10) and RID registration 
system codes (V code). The ICD-10 codes for CD and UC are K50 and K51, respectively. The RID 
codes for CD and UC are V130 and V131, respectively. The patients with IBD met the diagnostic 
criteria of clinical symptoms, endoscopy, histology, and radiology findings to register both ICD-10 
and V codes for CD or UC. The definition of IBD diagnosis based on both ICD-10 and V codes was 
confirmed using data from a total of 830 patients with IBD at Seoul National University Hospital, a 
tertiary referral hospital in South Korea. The sensitivities for the diagnosis of CD and UC were 94.5% 
(312/330) and 96.4% (482/500), respectively [8]. Patients newly diagnosed with IBD between 2010 and 
2014 were defined as the incident group. Patients diagnosed with IBD before 2010 and were 
diagnosed using the same ICD-10 and V codes between 2010 and 2014 were defined as the prevalent 
group. We identified the history of IBD from 2002 to the index date. The IBD cohort included both 
incident and prevalent groups.  
2.2. Data Collection  
Data were randomly extracted from the general population without a history of CD, UC, or 
diabetes and matched by age, sex, body mass index (BMI), waist circumference, smoking, alcohol 
drinking, exercise, and income at a 1:5 ratio on the same index date. The matched control group was 
considered the non-IBD cohort. Subjects in both IBD and non-IBD cohorts were followed up from the 
index date to December 2016. Corticosteroid use within the first year from the diagnosis of IBD was 
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analyzed and adjusted. Baseline characteristics including age, sex, BMI, blood pressure, history of 
smoking and drinking behavior, place of residence, exercise, and initial laboratory findings, 
including hemoglobin, serum glucose, total cholesterol, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma glutamyltransferase (GGT), and triglycerides, were investigated. 
Smoking behavior was classified as current smoker vs. ex-smoker or non-smoker. Alcohol drinking 
behavior was defined as ‘yes’ if exceeding 30 g per day. Exercise was defined as moderate-intensity 
physical activity for 30 min per day, or vigorous-intensity exercise for 20 min per day, at least once a 
week, based on a questionnaire of the National Health Screening Program [9,10]. Normal waist 
circumference was defined as less than 90 cm in men and 80 cm in women. Overweight was defined 
as a BMI over 25. Metabolic syndrome was defined as a combination of hyperglycemia, central 
obesity, atherogenic dyslipidemia, and hypertension according to the National Cholesterol Education 
Program Expert Panel and Adult Treatment Panel III criteria. This study was approved by the 
Institutional Review Board (IRB) of the Seoul National University Hospital (IRB Number, H-1703-
107-840). 
2.3. End Points 
The end point of this study was newly diagnosed diabetes during the follow-up period in the 
IBD and non-IBD cohorts. Diabetes is identified using ICD-10 codes (E11–14) and the prescription of 
anti-diabetic medication from the NHI database. The operational definition of diabetes based on both 
ICD-10 codes and prescription data was validated by a previous study [11]. Patients diagnosed with 
diabetes within the first year from the index date (lag period) were excluded to eliminate the presence 
of prevalent diabetes which was not causally related to IBD in this study. The comparative risk of 
newly diagnosed diabetes in the IBD cohort was analyzed based on age, sex, BMI, comorbidities, and 
baseline glycemic profiles. During the follow-up, patients without newly developed diabetes were 
censored on the last day of the follow-up or death date. A total of 365 mortality cases (0.75%) were 
censored in this study.  
2.4. Statistical Analysis 
Baseline characteristics of IBD and non-IBD patients were analyzed using the Student’s t-test for 
continuous variables with normality assumption and χ2 test for categorical variables. A propensity 
score matching was performed to select non-IBD controls. The incidence rates of diabetes were 
calculated as the number of incident cases divided by the total follow-up period and presented as per 
1000 person-years. The hazard ratio (HR) for the risk of diabetes based on the presence of IBD was 
calculated after adjusting for covariates such as age, sex, BMI, exercise, smoking, drinking status, 
BMI, baseline blood glucose level, and steroid use using Cox-proportional hazard models. The 
incidence probability of diabetes among each group was estimated using Kaplan–Meier analysis and 
the log-rank test. A p-value less than 0.05 was considered statistically significant. SAS version 9.3 
(SAS Institute, Cary, NC, USA) and SPSS Version 20.0 (SPSS Inc., Chicago, IL, USA) were used for 
statistical analyses.  
3. Results 
3.1. Baseline Characteristics  
A total of 8070 IBD patients were compared with 40,350 non-IBD subjects from the general 
population matched by age, sex, BMI, waist circumference, smoking, drinking, exercise, and income. 
Among the IBD patients, 1735 patients (21.5%) had CD and 6335 patients (78.5%) had UC. The mean 
age of the study population was 45.0 ± 12.9 years and mean follow-up duration was 5.1 years. The 
study population consisted of 32,251 men (66.6%), and the mean age was 45 years. The baseline 
characteristics of IBD patients and non-IBD controls are shown in Table 1. The non-IBD controls were 
more likely to live in a rural area (p = 0.001) and have more frequent hypertension and dyslipidemia, 
higher hemoglobin, total cholesterol, serum ALT (alanine aminotransferase), AST (aspartate 
aminotransferase), GGT (gamma glutamyltransferase), glucose, and triglyceride levels (p < 0.001). The 
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non-IBD controls used less steroids (p < 0.001). The baseline characteristics of both CD and UC 
patients compared with non-IBD subjects are shown in Supplementary Table S1. 
Table 1. Baseline characteristics of the study population. 
 IBD Non-IBD p-Value 
No. of patients 8070 40,350  
Age, years * 45.0 ± 12.8 44.9 ± 13.1 0.3230 
Male† (%) 5371 (66.6) 26,880 (66.6) 0.9142 
Height, cm * 166.4 ± 8.8 166.4 ± 8.6 0.5713 
Body weight, kg * 63.4 ± 11.2 63.3 ± 11.0 0.4491 
BMI, kg/m2 * 22.8 ± 3.0 22.8 ± 2.9 0.6091 
<18.5 † 518 (6.4) 2549 (6.3) 
0.6280 18.5–25.0 † 5762 (71.4) 29,023 (71.9) 
>25.0 † 1790 (22.2) 8778 (21.8) 
Waist circumference, cm * 78.8 ± 8.7 78.6 ± 8.7 0.1619 
Residence; Urban † (%) 3902 (48.4) 18,677 (46.3) 0.0008 
Smoking; Current † (%) 1133 (14.0) 5961 (14.8) 0.0889 
Drinking; No † (%) 7809 (96.8) 38,997 (96.7) 0.5868 
Exercise; Yes † (%) 4705 (58.3) 23,480 (58.2) 0.8529 
Underlying illness    
Hypertension † 1295 (16.1) 7376 (18.3) <0.0001 
Systolic BP, mmHg * 118.5 ± 13.7 120.2 ± 14.1 <0.0001 
Diastolic BP, mmHg * 74.1 ± 9.4 75.1 ± 9.7 <0.0001 
Dyslipidemia † 912 (11.3) 5896 (14.6) <0.0001 
Corticosteroid use; Yes † (%) 4080 (50.6) 14,810 (36.7) <0.0001 
Initial laboratory findings *   
Glucose, mg/dL 91.4 ± 10.9 92.6 ± 11.2 <0.0001 
Total cholesterol, mg/dL 182.6 ± 35.6 191.7 ± 35.4 <0.0001 
Hemoglobin, g/dL 13.8 ± 1.7 14.2 ± 1.6 <0.0001 
ALT, IU/L ‡ 19.3 (19.1–19.5) 21.5 (21.4–21.6) <0.0001 
AST, IU/L ‡ 22.8 (22.6–22.9) 23.8 (23.7–23.9) <0.0001 
GGT, IU/L ‡ 23.1 (22.8–23.4) 25.2 (25.0–25.4) <0.0001 
Triglyceride, mg/d L ‡ 99.0 (97.9–100.2) 103.8 (103.2–104.4) <0.0001 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood 
pressure; GGT, gamma glutamyltransferase; IBD, inflammatory bowel disease; IU, international unit; 
* Mean ± standard deviation; † Number (%); ‡ Median (95% confidence interval). 
3.2. Incidence and Risk of Diabetes 
During the follow-up, the incidence rate of diabetes in IBD patients and non-IBD controls was 
23.19 and 22.02 per 1000 person-years, respectively (Table 2). The risk of diabetes in patients with IBD 
was significantly higher than in non-IBD controls after adjusting for age, sex, smoking, drinking, and 
exercise (hazard ratio (HR), 1.091; 95% confidence interval (CI), 1.008–1.180, p = 0.031). The adjusted 
HR for diabetes was 1.410 (95% CI, 1.185–1.679; p < 0.001) in CD and 1.040 (95% CI, 0.955–1.133) in 
UC, respectively, compared with non-IBD controls (Model 3 in Table 2). The adjusted HRs for 
diabetes when adjusting for BMI and baseline blood glucose level also demonstrated a significantly 
higher risk of diabetes in the IBD cohort compared with the non-IBD cohort (HR, 1.154; 95% CI, 
1.067–1.249; p < 0.001; Model 4 in Table 2). In addition, after adjusting for steroid use, the risk of 
diabetes in the IBD cohort was significantly higher than in the non-IBD cohort (HR, 1.135; 95% CI, 
1.048–1.228; p = 0.002; Model 5 in Table 2). The HR for diabetes was 1.677 (95% CI, 1.408–1.997; p < 0.001) 
compared with the non-IBD cohort even after adjusting for age, sex, smoking, drinking, exercise, 
BMI, baseline blood glucose level, and steroid use, especially in CD patients. However, the risk of 
diabetes between non-IBD and UC cohorts after adjusting for age, sex, smoking, drinking, exercise, 
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BMI, baseline blood glucose level, and steroid use was not significantly different (adjusted HR, 1.061; 95% 
CI, 0.973–1.156). 
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Table 2. Incidence and risk of diabetes in inflammatory bowel disease. 
  
N Diabetes IR 
HR (95% CI) * 
  Model 1 † Model 2 ‡ Model 3 § Model 4 ‖ Model 5 
Control 40,350 3724 22.02 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 
IBD 8070 743 23.19 1.064 (0.984–1.152) 1.088 (1.006–1.177) 1.091 (1.008–1.180) 1.154 (1.067–1.249) 1.135 (1.048–1.228) 
p–value    0.1209 0.0356 0.0307 0.0004 0.0018 
CD 1735 132 18.83 0.859 (0.722–1.021) 1.420 (1.193–1.691) 1.410 (1.185–1.679) 1.697 (1.425–2.020) 1.677 (1.408–1.997) 
UC 6335 611 24.41 1.122 (1.030–1.223) 1.036 (0.951–1.129) 1.040 (0.955–1.133) 1.080 (0.991–1.176) 1.061 (0.973–1.156) 
p–value    0.0049 0.0004 0.0005 <0.0001 <0.0001 
CD, Crohn’s disease; CI, confidence intervals; HR, hazard ratios; IBD, inflammatory bowel disease; IR, incidence rates; N, number; Ref., reference; UC, ulcerative 
colitis; * Median (95% confidence interval); † Model 1: Non-adjusted; ‡ Model 2: Adjusted by age and sex; § Model 3: Adjusted by age, sex, smoke, drink, and 
exercise; ‖ Model 4: Adjusted by age, sex, smoke, drink, exercise, BMI, and baseline blood glucose level, Model 5: Adjusted by age, sex, smoke, drink, exercise, BMI, 
baseline blood glucose level, and steroid use. 
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3.3. Subgroup Analysis 
The age-related incidence rate of diabetes in patients with IBD compared with non-IBD controls 
was analyzed (Figure 1). The incidence probabilities among CD, UC, and non-IBD cohorts, including 
all ages of the study population, were not significantly different (Figure 1A). However, patients with 
CD and UC showed significantly higher incidence probabilities compared with non-IBD subjects in 
the under 40 years of age subgroup (Figure 1B). The difference in incidence probabilities between 
IBD and non-IBD cohorts was less significant in the over 40 years of age subgroup (Figure 1C). The 
incidence rate of diabetes (per 1000 person-years) in IBD patients and controls in their 20s was 6.0 
and 3.0, respectively (HR, 2.001; 95% CI 1.226–3.265; p = 0.0055). In their 30s, the incidence rate of 
diabetes (per 1000 person–years) in IBD patients and controls was 9.5 and 6.0, respectively (HR, 1.608; 
95% CI 1.245–2.077; p = 0.0003). However, in individuals over 40 years of age, the difference of 
incidence rates of diabetes between IBD and non-IBD cohorts was not significant (Supplementary 
Table S2 and Figure 2). The incidence rate of diabetes increased based on age in both cohorts; 
however, the HR of diabetes was significantly higher in younger IBD patients compared with same-
aged non-IBD controls. The effect of both CD and UC on the development of diabetes was 
significantly more prominent in younger patients under 40 years of age (in CD: HR, 2.395 vs. 1.563; 
in UC: HR, 1.589 vs. 1.020; p-value based on interaction analysis, 0.0026). The effect of IBD on the 
development of diabetes among subgroups classified based on sex, waist circumference, metabolic 
syndrome, overweight, and steroid use was not significantly different (Table 3). 
  
(A) (B) 
 
(C) 
Figure 1. Incidence probability of diabetes in patients with Crohn’s disease (CD) and ulcerative colitis 
(UC) compared with age-matched non-IBD (inflammatory bowel disease) controls based on age 
group. Patients with CD (red line), UC (green line), and non-IBD controls (black line). All ages (A), 
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under 40 years (B), over 40 years (C). CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, 
ulcerative colitis. 
 
Figure 2. Incidence rate (left Y axis, column) and hazard ratio (right Y axis, line with 95% confidence 
intervals; CI) of diabetes in patients with inflammatory bowel disease (IBD) compared with non-IBD 
controls based on age group. Error bars represent 95% CIs. * Indicates p < 0.05; HR, hazard ratio; IBD, 
inflammatory bowel disease; UC, ulcerative colitis. 
Table 3. Subgroup analysis of risk for diabetes in inflammatory bowel disease. 
Subgroup IBD HR (95% CI) p-Value * 
p-Value for  
Interaction Analysis † 
Age 
<40 CD 2.395 (1.715–3.345) 
<0.0001 
0.0026 
 UC 1.589 (1.198–2.108) 
≥40 CD 1.563 (1.27–1.924) 
0.0001  UC 1.020 (0.932–1.116) 
Sex 
Male CD 1.674 (1.352–2.072) 
<0.0001 
0.8492 
 UC 1.074 (0.965–1.195) 
Female CD 1.745 (1.284–2.371) 
0.0017 
  UC 1.045 (0.903–1.201) 
Waist 
Circumference 
No CD 1.661 (1.352–2.040) 
<0.0001 
0.7684 
 UC 1.075 (0.967–1.195) 
Yes CD 1.714 (1.229–2.391) 
0.0063 
  UC 1.036 (0.892–1.202) 
Metabolic 
syndrome 
No CD 1.832 (1.480–2.269) 
<0.0001 
0.3152 
 UC 1.147 (1.020–1.290) 
Yes CD 1.576 (1.160–2.141) 
0.0120 
  UC 1.052 (0.926–1.195) 
Overweight 
No CD 1.682 (1.364–2.073) 
<0.0001 
0.4154 
 UC 1.006 (0.902–1.122) 
Yes CD 1.656 (1.203–2.28) 
0.0011 
  UC 1.172 (1.018–1.348) 
Steroid use 
No CD 1.558 (1.204–2.016) 
0.0027 
0.4088 
 UC 1.060 (0.932–1.206) 
Yes CD 1.781 (1.403–2.260) 
<0.0001 
  UC 1.051 (0.936–1.180) 
IBD, inflammatory bowel disease; HR, hazard ratios; CI, confidence intervals; CD, Crohn’s disease; 
UC, ulcerative colitis; * p-value represents the statistical significance of HR of diabetes in each 
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subgroup; † A p-value < 0.05 for interaction analysis implies statistically significant subgroup 
interactions with HR of diabetes in IBD patients. 
4. Discussion 
In the present Korean nationwide population-based study, the relationship between IBD and 
diabetes was investigated. After analyzing a total of 48,420 individuals in the NHI database, the 
incidence of diabetes in patients with IBD, and especially with CD, was significantly higher compared 
with subjects in the general population matched by age, sex, BMI, smoking, alcohol drinking, 
exercise, and income. To the best of our knowledge, this is the first epidemiologic study in which the 
incidence and risk of diabetes in patients with IBD have been evaluated. 
Based on a literature review, the causal relationship between IBD and diabetes is still 
controversial. In a cross-sectional study including 12,601 patients with IBD, type-1 diabetes was the 
third most common comorbidity in IBD patients (prevalence, 1.0%); however, the odds for type-1 
diabetes were not significantly elevated in both CD and UC patients [12]. A cross-sectional study 
using claims data in the United States reported that there was no significant association between IBD 
and type-1 diabetes [13]. A recent epidemiologic study of the NHI Survey in the United States also 
showed that the age-adjusted prevalence of type-1 and -2 diabetes was 10.1 (95% CI, 8.2–12.4) in 
patients with IBD and 8.6 (95% CI, 8.4–8.9) in individuals without IBD, respectively, but the difference 
was not statistically significant [14]. In contrast, a recent cross-sectional study from 47,325 IBD 
patients in Denmark showed that type-1 diabetes was significantly associated with both UC and CD 
[15]. In a case-control study of 1200 pediatric IBD patients, the prevalence of type-1 and -2 diabetes 
was also higher in UC patients than in controls (odds ratio, 2.7; 95% CI, 1.1–6.6) [16]. The first 
population-based cohort study from the United Kingdom Clinical Practice Research Datalink 
demonstrated a crude IBD incidence rate of 37.7 per 100,000 person-years in 141,170 patients with 
type-2 diabetes, and the use of dipeptidyl peptidase-4 inhibitors was associated with an increased 
risk of UC, but not CD [17]. In the present study, the risk of type-1 and -2 diabetes after adjusting for 
steroid use and all risk factors for diabetes including age, sex, smoking, drinking, exercise, and BMI, 
the baseline blood glucose level was significantly higher in patients with CD, but not in patients with 
UC. Considering the results of large-scale population-based cohort studies, there may be a potential 
risk of type-1 and -2 diabetes in IBD, although there is still debate surrounding the causal relationship 
between IBD and diabetes due to the heterogeneity of the study design and population. 
The mechanism of chronic inflammation and genetic factors common to type-1 and -2 diabetes 
and IBD, especially CD, may play a crucial role in this phenomenon. One explanation for the 
relationship between IBD and diabetes is that IBD is associated with diabetes in terms of chronic 
inflammation and dysbiosis [18,19]. Increased permeability of the intestinal mucosa and disturbance 
of gut microbiota can activate systemic inflammation through T helper 17 lymphocytes, eventually 
leading to autoimmune diseases such as IBD and type-1 diabetes [20,21]. Crosstalk between diabetes 
and IBD is possible, due to the mechanisms involved in the breakdown of homeostasis [20]. Jurjus A 
et al. suggested that IBD and type-2 diabetes were linked through dysbiosis and multiple 
inflammatory consequences [18]. In several studies, adiponectin, leptin, and ghrelin levels in IBD 
patients differed from individuals without IBD [22–24]. Hypothetically, the correlation between IBD 
and diabetes diseases is based on common multiple inflammatory pathways such as nuclear factor 
kappa-B (NF-κB) [25]. However, the relationship between diabetes and IBD remains unclear and 
conflicting [26]. In previous studies on pathophysiology and genetic mutations of IBD and diabetes, 
evidence of genetic or epigenetic predisposition, common to both IBD and diabetes, was found. 
Several genetic loci variants related to the pathogenesis of IBD and diabetes have been reported. The 
gene mutations in protein tyrosine phosphatase non-receptor type (PTPN)2 and PTPN22 are a genetic 
variation that plays a role in the development of both CD and type-1 diabetes [27]. In type-1 diabetes, 
the PTPN2 mutation plays an important role in apoptosis of pancreatic beta cells but modulates 
intestinal epithelial barrier function and the innate immune response in CD [28–31]. However, in 
another study, the risk alleles for type-1 diabetes such as PTPN22, interleukin (IL)-27, and IL-10 loci 
J. Clin. Med. 2019, 8, 343 10 of 13 
 
were shown to protect against CD [32]. Regarding gut microbiome and dysbiosis, bile acid 
modification genes in gut microbiome were abundant in CD and type-2 diabetes patients [33]. 
The overall incidence of diabetes increases with age; however, IBD patients may be at a 
significant risk of developing diabetes even at a younger age compared with the general population. 
In the subgroup analysis in this study, a more prominent effect of CD and UC was found on the 
development of diabetes in younger age groups, especially those under 40 years of age. Younger CD 
patients under 40 years of age had a 2.4-fold higher risk of diabetes compared with the non-IBD 
controls. Even patients under 40 years of age with UC had a significantly higher risk of diabetes 
compared with the general population. These findings indicate that IBD has a critical role in the 
pathogenesis of diabetes in younger individuals at a relatively low risk of metabolic diseases. 
Therefore, physicians should be aware that young patients with IBD could develop diabetes. 
Shanahan F et al. reported that microbial disturbances, as an environmental factor in early life, 
contribute to the development of chronic inflammation and metabolic disorders [34]. Because insulin 
resistance is also associated with chronic inflammation, IBD can increase the risk of diabetes through 
inflammatory and metabolic signaling in younger patients [35]. Early exposure to environmental 
factors which affect the proportion of microbiota, such as early antibiotic exposure, increases the risk 
of IBD [36,37]. These environmental and genetic factors in young patients with IBD may affect glucose 
metabolism and result in diabetes. However, the pathogenesis of diabetes in younger patients 
remains unclear and further investigations are warranted. 
This study had several limitations including the retrospective cohort design. Type-1 and -2 
diabetes, as study end points, could not be distinguished in this study population. In addition, the 
risk of diabetes based on the severity of IBD could not be demonstrated because the NHI database 
had no information regarding the severity of IBD. However, the risk of developing diabetes related 
to IBD, especially CD in younger patients, was also significant regardless of steroid use, indicating 
the severe disease course of IBD. Further prospective studies may be needed to determine the risk of 
diabetes based on the severity of IBD. The study design, i.e., comparing IBD and non-IBD cohorts 
matched by multiple variables, might reveal intermediary factors in a possible causal relationship 
between IBD and diabetes due to overmatching. 
5. Conclusions 
In conclusion, patients with CD have a significantly increased risk of diabetes compared with 
non-IBD controls, regardless of steroid use. Therefore, regular monitoring of blood glucose levels 
should be considered for the early detection of diabetes in patients with CD, even in younger patients. 
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